Prospective Trial Shows Impact of Home OCT Guided Wet AMD Patient Management

Remote monitoring reduces office visit and treatment burden in some patients

Manassas, Virginia–(Newsfile Corp. – June 25, 2024) – Digital healthcare provider, Notal Vision, announced the results from the first-ever prospective clinical trial using home-based optical coherence tomography (OCT) to manage neovascular age-related macular degeneration (nvAMD) patients in an investigational setting have been published in RETINA©. The publication demonstrated a significant reduction in office visits and treatment frequency, while visual acuity remained stable.

The Institutional Review Board (IRB) approved trial enrolled 15 patients with nvAMD in at least one eye from three retina specialist practices in the US. A total of 21 eyes in the study were managed with home OCT over a period of 6 months. The patients received the home OCT device through the Notal Vision Monitoring Center, which also provided virtual support and patient education. Patients did not receive any training on use of the device in the physician’s office. The self-acquired scans were automatically uploaded to a secure cloud and reviewed periodically by the study investigators.

Physicians set time and structural biomarker-based thresholds to prompt notifications and assist in timely review of data. Treatment frequency and visual acuity outcomes were compared to the patients’ own past standard of care data, dating back to their diagnosis of nvAMD with a maximum of 2 years.

The reported results demonstrated a significant reduction in office visits and treatment frequency with the mean treatment interval increasing from 8 to 15.3 weeks. The mean visual acuity remained stable.1

The investigators also looked at patient adherence and ability to successfully use the device. Patient adherence to home OCT use was high, with on average 6.2 scans per week in each eye.1

The trial follows a series of home OCT based studies that have demonstrated the ability of nvAMD patients to self-image conveniently at home over extended periods.

Reference:

  1. Holekamp, Nancy M., et al. “Prospective trial of Home OCT guided management of treatment experienced nAMD patients.” RETINA (2024): 10-1097. DOI: 10.1097/IAE.0000000000004167

About Notal Vision

Notal Vision is a patient-centric ophthalmic remote monitoring services provider extending retinal disease monitoring from the clinic to the home, providing physicians with remote monitoring services to support their patient care between office visits. With a proven approach to home-based, self-operated diagnostics, AI-enabled data analysis, and patient engagement, our goal is to help doctors preserve patients’ vision. www.notalvision.com

The Notal Vision Monitoring Center (NVMC) is a remote, Medicare credentialed ophthalmic monitoring center and the epicenter of patient engagement. Led by practicing ophthalmologists and supported by certified ophthalmic professionals, the Monitoring Center offers a nationwide age-related macular degeneration (AMD) home monitoring service for patients.

The ForeseeHome® AMD Monitoring Program is a comprehensive program, which includes an FDA-cleared device that monitors visual changes in intermediate dry AMD patients at risk of vision loss from undiagnosed wet AMD.

With the addition of the SCANLY Home OCT system to the Notal Vision family of monitoring products, wet AMD patients are able to perform technician-free OCT scanning at home with rapid and self-guided fixation – critical components, especially for elderly patients frequently with pre-existing vision loss. The Notal Vision Monitoring Center provides patient data to the physician via the online SCANLY Portal. Physicians are provided 24/7 access to all their patients’ B-scan images from each SCANLY Home OCT scan with the location of the hypo-reflective spaces annotated on each B-scan. The Notal OCT Analyzer (NOA), a proprietary machine learning algorithm, performs automated analysis of the Home OCT scans and generates a report to the physician when a physician specified change is detected. Following physician receipt of a change notification, a patient may be brought to the office for further evaluation if warranted.

###

Media Contact:
Candice Morin
candicem@notalvision.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/214150

Staff

Recent Posts

Rapid Dose Announces Proposed Issuance of Shares as Payment of Director Fees

Burlington, Ontario--(Newsfile Corp. - December 24, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or…

2 hours ago

Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan

DUBLIN, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology…

2 hours ago

Carmell Announces PIPE Investment From Existing and New Investors To Support Commercial Build-out

PITTSBURGH, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused…

2 hours ago

AI/ML Innovations Closes Acquisition of Quantum Sciences Ltd.

Strategic Expansion into Cardio AI-Driven Healthcare SolutionsCollaboration to Enhance Patient-Centered Digital Healthcare TechnologiesWelcomes Key Industry…

5 hours ago

cbdMD Announces Company’s CEO Joins the Board of Directors

Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

19 hours ago

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

20 hours ago